Last 12 months
Inside the activity.
1 purchase rows · 24 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 2 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 4 |
| Jun 2026 | 0 | 7 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 04, 2020 Filed Dec 8, 2020 22:38 UTC |
Anevski PeterPresident and COO
|
SaleCommon Stock | 17,323 | $37.25 | $645,281.75 |
DisclosureSEC source: 0001209191-20-062339 · doc4.xml · nonDerivative · entry 1 Anevski Peter · CIK 0001576147 · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 171,677 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on September 3, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.59 to $37.585 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4). F3 · ownership.nature: The reportable securities are held directly by the PECO ANEVSKI 2020 SD LLC. Read SEC document |
| December 03, 2020 Filed Dec 4, 2020 01:05 UTC |
Schlanger David JDirector · Chief Executive Officer
|
SaleCommon Stock | 1,530 | $37.84 | $57,895.20 |
DisclosureSEC source: 0001209191-20-061697 · doc4.xml · nonDerivative · entry 6 Schlanger David J · CIK 0001576145 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 100,010 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.71 to $38.04 inclusive. F3 · ownership.nature: The reportable securities are held directly by the David J. Schlanger 2020 SD LLC. Read SEC document |
| December 03, 2020 Filed Dec 4, 2020 01:05 UTC |
Schlanger David JDirector · Chief Executive Officer
|
SaleCommon Stock | 38,470 | $37.09 | $1,426,852.30 |
DisclosureSEC source: 0001209191-20-061697 · doc4.xml · nonDerivative · entry 5 Schlanger David J · CIK 0001576145 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 101,540 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.71 to $37.69 inclusive. F3 · ownership.nature: The reportable securities are held directly by the David J. Schlanger 2020 SD LLC. Read SEC document |
| December 03, 2020 Filed Dec 4, 2020 01:04 UTC |
Anevski PeterPresident and COO
|
SaleCommon Stock | 605 | $37.89 | $22,923.45 |
DisclosureSEC source: 0001209191-20-061694 · doc4.xml · nonDerivative · entry 6 Anevski Peter · CIK 0001576147 · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 189,000 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on September 3, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.79 to $38.05 inclusive. F3 · ownership.nature: The reportable securities are held directly by the PECO ANEVSKI 2020 SD LLC. Read SEC document |
| December 03, 2020 Filed Dec 4, 2020 01:04 UTC |
Anevski PeterPresident and COO
|
SaleCommon Stock | 20,395 | $37.10 | $756,654.50 |
DisclosureSEC source: 0001209191-20-061694 · doc4.xml · nonDerivative · entry 5 Anevski Peter · CIK 0001576147 · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 189,605 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on September 3, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.78 to $37.72 inclusive. F3 · ownership.nature: The reportable securities are held directly by the PECO ANEVSKI 2020 SD LLC. Read SEC document |
| December 03, 2020 Filed Dec 4, 2020 21:39 UTC |
Payson NormanDirector
|
SaleCommon Stock | 5,500 | $37.08 | $203,940.00 |
DisclosureSEC source: 0001209191-20-061815 · doc4.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 550,500 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.82 to $37.67 inclusive. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 16:10 UTC |
BONDERMAN DAVID10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 53,476 | $37.56 | $2,008,735.03 |
DisclosureSEC source: 0001387131-20-010509 · pgny-form4.xml · nonDerivative · entry 2 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 15,352,612 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by TPG Biotech III. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.20 to $38.06 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnologies GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 15,254,748 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Progyny, Inc. (the "Issuer"). F7 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any. F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 16:10 UTC |
BONDERMAN DAVID10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 74,030 | $36.97 | $2,736,548.56 |
DisclosureSEC source: 0001387131-20-010509 · pgny-form4.xml · nonDerivative · entry 1 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 15,406,088 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by TPG Biotech III. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.62 to $37.19 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnologies GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 15,254,748 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Progyny, Inc. (the "Issuer"). F7 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any. F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 01:05 UTC |
Schlanger David JDirector · Chief Executive Officer
|
SaleCommon Stock | 24,859 | $36.48 | $906,856.32 |
DisclosureSEC source: 0001209191-20-061697 · doc4.xml · nonDerivative · entry 4 Schlanger David J · CIK 0001576145 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 140,010 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.21 to $37.00 inclusive. F3 · ownership.nature: The reportable securities are held directly by the David J. Schlanger 2020 SD LLC. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 01:05 UTC |
Schlanger David JDirector · Chief Executive Officer
|
SaleCommon Stock | 15,141 | $35.90 | $543,561.90 |
DisclosureSEC source: 0001209191-20-061697 · doc4.xml · nonDerivative · entry 3 Schlanger David J · CIK 0001576145 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 164,869 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.21 to $36.20 inclusive. F3 · ownership.nature: The reportable securities are held directly by the David J. Schlanger 2020 SD LLC. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 01:04 UTC |
Anevski PeterPresident and COO
|
SaleCommon Stock | 13,572 | $36.47 | $494,970.84 |
DisclosureSEC source: 0001209191-20-061694 · doc4.xml · nonDerivative · entry 4 Anevski Peter · CIK 0001576147 · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 210,000 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on September 3, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.21 to $36.98 inclusive. F3 · ownership.nature: The reportable securities are held directly by the PECO ANEVSKI 2020 SD LLC. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 01:04 UTC |
Anevski PeterPresident and COO
|
SaleCommon Stock | 7,428 | $35.91 | $266,739.48 |
DisclosureSEC source: 0001209191-20-061694 · doc4.xml · nonDerivative · entry 3 Anevski Peter · CIK 0001576147 · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 223,572 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on September 3, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.21 to $36.20 inclusive. F3 · ownership.nature: The reportable securities are held directly by the PECO ANEVSKI 2020 SD LLC. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 21:39 UTC |
Payson NormanDirector
|
SaleCommon Stock | 3,500 | $36.49 | $127,715.00 |
DisclosureSEC source: 0001209191-20-061815 · doc4.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 556,000 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.24 to $36.98 inclusive. F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 21:39 UTC |
Payson NormanDirector
|
SaleCommon Stock | 2,000 | $35.89 | $71,780.00 |
DisclosureSEC source: 0001209191-20-061815 · doc4.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 559,500 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.22 to $36.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4) and (7). F3 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| December 02, 2020 Filed Dec 15, 2020 23:19 UTC |
Livingston Mark S.Chief Financial Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,626 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001209191-20-063596 · doc4.xml · derivative · entry 4 Livingston Mark S. · CIK 0001824161 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,252 Underlying: Common Stock · 20,626 shares Expires 2029-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the Option vested on May 29, 2020, with the remaining shares vesting in equal monthly installments thereafter through May 29, 2023, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 02, 2020 Filed Dec 15, 2020 23:19 UTC |
Livingston Mark S.Chief Financial Officer
|
SaleCommon Stock | 10,662 | $36.54 | $389,589.48 |
DisclosureSEC source: 0001209191-20-063596 · doc4.xml · nonDerivative · entry 3 Livingston Mark S. · CIK 0001824161 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,225 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.40 to $36.757 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2020 Filed Dec 15, 2020 23:19 UTC |
Livingston Mark S.Chief Financial Officer
|
Tax withholdingCommon Stock | 11,239 | $36.59 | $411,235.01 |
DisclosureSEC source: 0001209191-20-063596 · doc4.xml · nonDerivative · entry 2 Livingston Mark S. · CIK 0001824161 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,887 Read SEC document |
| December 02, 2020 Filed Dec 15, 2020 23:19 UTC |
Livingston Mark S.Chief Financial Officer
|
Exercise / conversionCommon Stock | 20,626 | $3.95 | $81,472.70 |
DisclosureSEC source: 0001209191-20-063596 · doc4.xml · nonDerivative · entry 1 Livingston Mark S. · CIK 0001824161 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,126 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:05 UTC |
Schlanger David JDirector · Chief Executive Officer
|
SaleCommon Stock | 31,462 | $35.68 | $1,122,564.16 |
DisclosureSEC source: 0001209191-20-061697 · doc4.xml · nonDerivative · entry 2 Schlanger David J · CIK 0001576145 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 180,010 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.14 to $36.13 inclusive. F3 · ownership.nature: The reportable securities are held directly by the David J. Schlanger 2020 SD LLC. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:05 UTC |
Schlanger David JDirector · Chief Executive Officer
|
SaleCommon Stock | 8,538 | $34.83 | $297,378.54 |
DisclosureSEC source: 0001209191-20-061697 · doc4.xml · nonDerivative · entry 1 Schlanger David J · CIK 0001576145 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 211,472 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.13 to $35.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6), (7) and (8). F3 · ownership.nature: The reportable securities are held directly by the David J. Schlanger 2020 SD LLC. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:04 UTC |
Anevski PeterPresident and COO
|
SaleCommon Stock | 16,400 | $35.68 | $585,152.00 |
DisclosureSEC source: 0001209191-20-061694 · doc4.xml · nonDerivative · entry 2 Anevski Peter · CIK 0001576147 · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 231,000 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on September 3, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.14 to $36.05 inclusive. F3 · ownership.nature: The reportable securities are held directly by the PECO ANEVSKI 2020 SD LLC. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:04 UTC |
Anevski PeterPresident and COO
|
SaleCommon Stock | 4,600 | $34.84 | $160,264.00 |
DisclosureSEC source: 0001209191-20-061694 · doc4.xml · nonDerivative · entry 1 Anevski Peter · CIK 0001576147 · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 247,400 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on September 3, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.13 to $35.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6), (7) and (8). F3 · ownership.nature: The reportable securities are held directly by the PECO ANEVSKI 2020 SD LLC. Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 22:16 UTC |
Payson NormanDirector
|
GiftCommon Stock | 387,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-060922 · doc4.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F3 · kind: On November 30, 2020, Norman C. Payson and Robert L. Carson, Trustee of the Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT") gifted (i) 193,800 shares to the SHP Trust and (ii) 193,799 shares to the DJP Trust. F4 · ownership.nature: The reportable securities are directly held by NCP GRAT. The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 22:16 UTC |
Payson NormanDirector
|
GiftCommon Stock | 387,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-060922 · doc4.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: On November 30, 2020, Melinda B. Payson and Robert L. Carson, Trustee of the Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT") gifted (i) 193,800 shares to Devon Judith Payson Irrevocable Trust 2000 ("DJP Trust") and (ii) 193,799 shares to Sunny Holly Payson Irrevocable Trust 2000 ("SHP Trust"). F2 · ownership.nature: The reportable securities are directly held by MBP GRAT. The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 16:13 UTC |
BONDERMAN DAVID10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 15,778 | $36.09 | $569,415.40 |
DisclosureSEC source: 0001387131-20-010414 · pgny-form4_113020.xml · nonDerivative · entry 2 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 15,480,118 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by TPG Biotech III. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.62 to $36.57 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnologies GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 15,480,118 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Progyny, Inc. (the "Issuer"). F5 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any. F6 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 16:13 UTC |
BONDERMAN DAVID10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 59,222 | $35.13 | $2,080,522.16 |
DisclosureSEC source: 0001387131-20-010414 · pgny-form4_113020.xml · nonDerivative · entry 1 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 15,495,896 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by TPG Biotech III. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.60 to $35.585 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnologies GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 15,480,118 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Progyny, Inc. (the "Issuer"). F5 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any. F6 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:43 UTC |
KPCB XIII Associates, LLC10% owner
|
OtherCommon Stock | 522,904 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-131677 · tm2037533d1_form4.xml · nonDerivative · entry 3 KLEINER PERKINS CAUFIELD & BYERS XIII, LLC · CIK 0001435899 · 10% owner KPCB XIII Associates, LLC · CIK 0001500595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F5 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by XIII Associates without consideration to its members. F6 · ownership.nature: XIII Associates holds no shares of Common Stock of the Issuer following the pro-rata in-kind distribution of such shares to its members. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:43 UTC |
KPCB XIII Associates, LLC10% owner
|
OtherCommon Stock | 522,904 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-131677 · tm2037533d1_form4.xml · nonDerivative · entry 2 KLEINER PERKINS CAUFIELD & BYERS XIII, LLC · CIK 0001435899 · 10% owner KPCB XIII Associates, LLC · CIK 0001500595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 522,904 F3 · kind: Represents a change in the form of ownership as a result of the receipt by XIII Associates of shares in the Fund Distribution. F4 · ownership.nature: Consists of 522,904 shares of Common Stock of the Issuer held by XIII Associates. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:43 UTC |
KPCB XIII Associates, LLC10% owner
|
OtherCommon Stock | 1,398,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-131677 · tm2037533d1_form4.xml · nonDerivative · entry 1 KLEINER PERKINS CAUFIELD & BYERS XIII, LLC · CIK 0001435899 · 10% owner KPCB XIII Associates, LLC · CIK 0001500595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,026,296 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Kleiner Perkins Caufield & Byers XIII, LLC ("KPCB XIII") without consideration to its members (the "Fund Distribution"). Excludes 101,100 shares of Common Stock for which a change in the form of beneficial ownership for individuals and entities associated with Kleiner Perkins Caufield & Byers occurred. F2 · ownership.direct: The shares are directly held by KPCB XIII. All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee." The managing member of KPCB XIII is KPCB XIII Associates, LLC ("XIII Associates"). The voting and dispositive control over the shares is shared by individual managing directors of XIII Associates, none of whom has veto power. Excludes 869,153 shares of Common Stock beneficially owned by individuals and entities associated with Kleiner Perkins Caufield & Byers and held for convenience in the name of "KPCB Holdings, Inc. as nominee," for the accounts of such individuals and entities who each exercise their own voting and dispositive control over such shares. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:24 UTC |
SEIDENBERG BETH CDirector
|
OtherCommon Stock | 24,238 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-061239 · doc4.xml · nonDerivative · entry 4 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,141 F6 · kind: Represents a change in the form of ownership as a result of the receipt by the Reporting Person of shares in the Fund Distribution. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:24 UTC |
SEIDENBERG BETH CDirector
|
OtherCommon Stock | 522,904 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-061239 · doc4.xml · nonDerivative · entry 3 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F5 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by XIII Associates without consideration to its members. F4 · ownership.nature: Consists of shares of Common Stock of the Issuer held by XIII Associates. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:24 UTC |
SEIDENBERG BETH CDirector
|
OtherCommon Stock | 522,904 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-061239 · doc4.xml · nonDerivative · entry 2 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 522,904 F3 · kind: Represents a change in the form of ownership as a result of the receipt by XIII Associates of shares in the Fund Distribution. F4 · ownership.nature: Consists of shares of Common Stock of the Issuer held by XIII Associates. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 22:24 UTC |
SEIDENBERG BETH CDirector
|
OtherCommon Stock | 1,398,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-061239 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 12,026,296 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Kleiner Perkins Caufield & Byers XIII, LLC ("KPCB XIII") without consideration to its members (the "Fund Distribution"). Excludes 101,100 shares of Common Stock for which a change in the form of beneficial ownership for individuals and entities associated with Kleiner Perkins Caufield & Byers occurred. F2 · ownership.nature: The shares are directly held by KPCB XIII. All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XIII is KPCB XIII Associates, LLC ("XIII Associates"). The voting and dispositive control over the shares is shared by individual managing directors of XIII Associates, none of whom has veto power. Excludes 869,153 shares of Common Stock beneficially owned by individuals and entities associated with Kleiner Perkins Caufield & Byers and held for convenience in the name of "KPCB Holdings, Inc. as nominee," for the accounts of such individuals and entities who each exercise their own voting and dispositive control over such shares. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 27, 2020 Filed Dec 1, 2020 22:14 UTC |
SEIDENBERG BETH CDirector
|
SaleCommon Stock | 19,231 | $36.00 | $692,316.00 |
DisclosureSEC source: 0001209191-20-060917 · doc4.xml · nonDerivative · entry 1 SEIDENBERG BETH C · CIK 0001184592 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 38,461 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 13, 2020. F2 · ownership.nature: The shares are directly held by The Seidenberg/Vogel Rev Trust 3/6/03 Paul Voge (the "Trust"). The Reporting Person is a trustee of the Trust. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 21:50 UTC |
Payson NormanDirector
|
SaleCommon Stock | 162 | $34.62 | $5,608.44 |
DisclosureSEC source: 0001209191-20-060533 · doc4.xml · nonDerivative · entry 15 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 561,500 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.56 to $34.73 inclusive. F6 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 21:50 UTC |
Payson NormanDirector
|
SaleCommon Stock | 3,770 | $34.11 | $128,594.70 |
DisclosureSEC source: 0001209191-20-060533 · doc4.xml · nonDerivative · entry 14 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 561,662 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.565 to $34.52 inclusive. F6 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 21:50 UTC |
Payson NormanDirector
|
SaleCommon Stock | 568 | $33.06 | $18,778.08 |
DisclosureSEC source: 0001209191-20-060533 · doc4.xml · nonDerivative · entry 13 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 565,432 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.57 to $33.55 inclusive. F6 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 21:50 UTC |
Payson NormanDirector
|
SaleCommon Stock | 219 | $34.62 | $7,581.78 |
DisclosureSEC source: 0001209191-20-060533 · doc4.xml · nonDerivative · entry 12 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 387,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.56 to $34.73 inclusive. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 21:50 UTC |
Payson NormanDirector
|
SaleCommon Stock | 5,025 | $34.11 | $171,402.75 |
DisclosureSEC source: 0001209191-20-060533 · doc4.xml · nonDerivative · entry 11 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 387,818 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.565 to $34.52 inclusive. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 21:50 UTC |
Payson NormanDirector
|
SaleCommon Stock | 756 | $33.06 | $24,993.36 |
DisclosureSEC source: 0001209191-20-060533 · doc4.xml · nonDerivative · entry 10 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 392,843 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.57 to $33.55 inclusive. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 21:50 UTC |
Payson NormanDirector
|
SaleCommon Stock | 219 | $34.62 | $7,581.78 |
DisclosureSEC source: 0001209191-20-060533 · doc4.xml · nonDerivative · entry 9 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 387,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.56 to $34.73 inclusive. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 21:50 UTC |
Payson NormanDirector
|
SaleCommon Stock | 5,025 | $34.11 | $171,402.75 |
DisclosureSEC source: 0001209191-20-060533 · doc4.xml · nonDerivative · entry 8 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 387,818 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.565 to $34.52 inclusive. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 21:50 UTC |
Payson NormanDirector
|
SaleCommon Stock | 756 | $33.06 | $24,993.36 |
DisclosureSEC source: 0001209191-20-060533 · doc4.xml · nonDerivative · entry 7 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 392,843 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.57 to $33.55 inclusive. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 21:51 UTC |
Greenbaum LisaEVP, Chief Client Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001209191-20-060534 · doc4.xml · derivative · entry 4 Greenbaum Lisa · CIK 0001791866 · EVP, Chief Client Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,002 Underlying: Common Stock · 6,000 shares Expires 2029-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the Option vested on June 3, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 21:51 UTC |
Greenbaum LisaEVP, Chief Client Officer
|
SaleCommon Stock | 2,689 | $32.57 | $87,580.73 |
DisclosureSEC source: 0001209191-20-060534 · doc4.xml · nonDerivative · entry 3 Greenbaum Lisa · CIK 0001791866 · EVP, Chief Client Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,044 F2 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 22, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.56 to $32.574 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 21:51 UTC |
Greenbaum LisaEVP, Chief Client Officer
|
Tax withholdingCommon Stock | 3,311 | $32.61 | $107,971.71 |
DisclosureSEC source: 0001209191-20-060534 · doc4.xml · nonDerivative · entry 2 Greenbaum Lisa · CIK 0001791866 · EVP, Chief Client Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,733 F1 · price: The price reported in Column 4 is a weighted average price. These shares were withheld in multiple transactions at prices ranging from $32.60 to $32.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares withheld at each separate price within the range set forth in this footnote. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 21:51 UTC |
Greenbaum LisaEVP, Chief Client Officer
|
Exercise / conversionCommon Stock | 6,000 | $3.96 | $23,760.00 |
DisclosureSEC source: 0001209191-20-060534 · doc4.xml · nonDerivative · entry 1 Greenbaum Lisa · CIK 0001791866 · EVP, Chief Client Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 18:53 UTC |
Bealer JenniferEVP, General Counsel
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,438 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001209191-20-060338 · doc4.xml · derivative · entry 8 Bealer Jennifer · CIK 0001789513 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,126 Underlying: Common Stock · 3,438 shares Expires 2029-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the Option vested on May 23, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 18:53 UTC |
Bealer JenniferEVP, General Counsel
|
SaleCommon Stock | 1,527 | $30.50 | $46,573.50 |
DisclosureSEC source: 0001209191-20-060338 · doc4.xml · nonDerivative · entry 6 Bealer Jennifer · CIK 0001789513 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,606 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 15, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $30.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 18:53 UTC |
Bealer JenniferEVP, General Counsel
|
Tax withholdingCommon Stock | 1,911 | $30.64 | $58,553.04 |
DisclosureSEC source: 0001209191-20-060338 · doc4.xml · nonDerivative · entry 5 Bealer Jennifer · CIK 0001789513 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,133 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.